Richard Glickman Buys 31,000 Shares of enGene Therapeutics
Glickman enhances his position in enGene Therapeutics with a significant share purchase.
Key Points
- Richard Glickman acquired 31,000 shares of enGene Therapeutics on June 16, 2026.
- enGene Therapeutics trades on NasdaqCM with a market cap of $117.2 million and a 52-week range of $1.40 to $12.25.
- The company focuses on genetic medicines for bladder cancer, with its lead product candidate in Phase 2 trials.
Richard Glickman, a notable figure associated with enGene Therapeutics Inc., has increased his investment in the company. On June 16, 2026, he purchased 31,000 shares of the NasdaqCM-listed biotechnology firm. This transaction was executed without a specified cost per share, reflecting a strategic move to enhance his position in the company.
enGene Therapeutics Stock Snapshot
Shares of enGene Therapeutics, trading under the ticker ENGN on NasdaqCM, recently hovered around $1.75. The company boasts a market capitalization of approximately $117.2 million. Although not currently profitable, enGene has a forward P/E ratio listed as negative, given its earnings per share of -$2.18. The stock's 52-week performance has seen it dip to a low of $1.40 and rise as high as $12.25. It has a 50-day moving average of $4.33 and a 200-day moving average of $7.13. Financial health metrics include a current ratio of 12.57, a quick ratio of 12.07, and a debt-to-equity ratio of 13.07.
About enGene Therapeutics
enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada. It focuses on developing genetic medicines aimed at treating bladder cancer. The company's primary product candidate, detalimogene voraplasmid, is a monotherapy targeting non-muscle invasive bladder cancer and is currently in Phase 2 trials. The company was previously known as enGene Holdings Inc. and rebranded to its current name in April 2026. enGene is led by CEO Mr. Ronald H. W. Cooper and operates with a team of 81 employees.
Bottom Line
Richard Glickman's purchase of 31,000 shares underscores his confidence in enGene Therapeutics' potential. The company, while still in the clinical stages, is advancing its pipeline with a focus on innovative genetic therapies. Investors and analysts will be watching closely as enGene continues its development, particularly with its lead product candidate progressing through clinical trials. This insider activity, while noteworthy, is reported after the fact and should be considered with other market factors.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.